These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 12855645)

  • 41. Aberrant promoter methylation of the transcription factor genes PAX5 alpha and beta in human cancers.
    Palmisano WA; Crume KP; Grimes MJ; Winters SA; Toyota M; Esteller M; Joste N; Baylin SB; Belinsky SA
    Cancer Res; 2003 Aug; 63(15):4620-5. PubMed ID: 12907641
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Epigenetic inactivation of the RUNX3 gene in lung cancer.
    Sato K; Tomizawa Y; Iijima H; Saito R; Ishizuka T; Nakajima T; Mori M
    Oncol Rep; 2006 Jan; 15(1):129-35. PubMed ID: 16328045
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
    Zhong S; Fields CR; Su N; Pan YX; Robertson KD
    Oncogene; 2007 Apr; 26(18):2621-34. PubMed ID: 17043644
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Differential expression of the LAMB3 and LAMC2 genes between small cell and non-small cell lung carcinomas.
    Manda R; Kohno T; Niki T; Yamada T; Takenoshita S; Kuwano H; Yokota J
    Biochem Biophys Res Commun; 2000 Aug; 275(2):440-5. PubMed ID: 10964684
    [TBL] [Abstract][Full Text] [Related]  

  • 45. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
    Ibanez de Caceres I; Cortes-Sempere M; Moratilla C; Machado-Pinilla R; Rodriguez-Fanjul V; Manguán-García C; Cejas P; López-Ríos F; Paz-Ares L; de CastroCarpeño J; Nistal M; Belda-Iniesta C; Perona R
    Oncogene; 2010 Mar; 29(11):1681-90. PubMed ID: 20023704
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation.
    Hopkins-Donaldson S; Ziegler A; Kurtz S; Bigosch C; Kandioler D; Ludwig C; Zangemeister-Wittke U; Stahel R
    Cell Death Differ; 2003 Mar; 10(3):356-64. PubMed ID: 12700635
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Aberrant methylation of IL-12Rbeta2 gene in lung adenocarcinoma cells is associated with unfavorable prognosis.
    Suzuki M; Iizasa T; Nakajima T; Kubo R; Iyoda A; Hiroshima K; Nakatani Y; Fujisawa T
    Ann Surg Oncol; 2007 Sep; 14(9):2636-42. PubMed ID: 17602269
    [TBL] [Abstract][Full Text] [Related]  

  • 48. DNA methylation profiles of lung tumors.
    Toyooka S; Toyooka KO; Maruyama R; Virmani AK; Girard L; Miyajima K; Harada K; Ariyoshi Y; Takahashi T; Sugio K; Brambilla E; Gilcrease M; Minna JD; Gazdar AF
    Mol Cancer Ther; 2001 Nov; 1(1):61-7. PubMed ID: 12467239
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Allelic loss on chromosome 3p21.3 and promoter hypermethylation of semaphorin 3B in non-small cell lung cancer.
    Kuroki T; Trapasso F; Yendamuri S; Matsuyama A; Alder H; Williams NN; Kaiser LR; Croce CM
    Cancer Res; 2003 Jun; 63(12):3352-5. PubMed ID: 12810670
    [TBL] [Abstract][Full Text] [Related]  

  • 50. DNA methylation profiling defines clinically relevant biological subsets of non-small cell lung cancer.
    Walter K; Holcomb T; Januario T; Du P; Evangelista M; Kartha N; Iniguez L; Soriano R; Huw L; Stern H; Modrusan Z; Seshagiri S; Hampton GM; Amler LC; Bourgon R; Yauch RL; Shames DS
    Clin Cancer Res; 2012 Apr; 18(8):2360-73. PubMed ID: 22261801
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering.
    Girard L; Zöchbauer-Müller S; Virmani AK; Gazdar AF; Minna JD
    Cancer Res; 2000 Sep; 60(17):4894-906. PubMed ID: 10987304
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
    Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
    Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular genetics of small cell lung carcinoma.
    Wistuba II; Gazdar AF; Minna JD
    Semin Oncol; 2001 Apr; 28(2 Suppl 4):3-13. PubMed ID: 11479891
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Epigenetic inactivation of checkpoint kinase 2 gene in non-small cell lung cancer and its relationship with clinicopathological features.
    Kim DS; Kim MJ; Lee JY; Lee SM; Choi JE; Lee SY; Park JY
    Lung Cancer; 2009 Aug; 65(2):247-50. PubMed ID: 19362748
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neutral endopeptidase: variable expression in human lung, inactivation in lung cancer, and modulation of peptide-induced calcium flux.
    Cohen AJ; Bunn PA; Franklin W; Magill-Solc C; Hartmann C; Helfrich B; Gilman L; Folkvord J; Helm K; Miller YE
    Cancer Res; 1996 Feb; 56(4):831-9. PubMed ID: 8631021
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inactivation of O6-methylguanine-DNA methyltransferase by promoter CpG island hypermethylation in gastric cancers.
    Bae SI; Lee HS; Kim SH; Kim WH
    Br J Cancer; 2002 Jun; 86(12):1888-92. PubMed ID: 12085181
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Methylated +322-327 CpG site decreases hOGG1 mRNA expression in non-small cell lung cancer.
    Zeng Y; Zhu J; Qin H; Shen D; Lei Z; Li W; Ding Z; Huang JA; Liu Z
    Oncol Rep; 2017 Jul; 38(1):529-537. PubMed ID: 28586012
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Aberrant promoter methylation of multiple genes in non-small cell lung cancers.
    Zöchbauer-Müller S; Fong KM; Virmani AK; Geradts J; Gazdar AF; Minna JD
    Cancer Res; 2001 Jan; 61(1):249-55. PubMed ID: 11196170
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma.
    Sugita M; Geraci M; Gao B; Powell RL; Hirsch FR; Johnson G; Lapadat R; Gabrielson E; Bremnes R; Bunn PA; Franklin WA
    Cancer Res; 2002 Jul; 62(14):3971-9. PubMed ID: 12124329
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Epigenetic inactivation of the RAS-effector gene RASSF2 in lung cancers.
    Kaira K; Sunaga N; Tomizawa Y; Yanagitani N; Ishizuka T; Saito R; Nakajima T; Mori M
    Int J Oncol; 2007 Jul; 31(1):169-73. PubMed ID: 17549418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.